|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
CA2055168A1
(en)
|
1990-11-21 |
1992-05-22 |
Walter Fiers |
Tnf-muteins
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
US5753230A
(en)
|
1994-03-18 |
1998-05-19 |
The Scripps Research Institute |
Methods and compositions useful for inhibition of angiogenesis
|
|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
|
MX9707453A
(es)
|
1995-03-30 |
1997-12-31 |
Pfizer |
Derivados de quinazolina.
|
|
GB9508537D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
|
HU228446B1
(en)
|
1996-04-12 |
2013-03-28 |
Warner Lambert Co |
Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
|
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
|
ZA986729B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
|
US7229619B1
(en)
|
2000-11-28 |
2007-06-12 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
MXPA05000511A
(es)
|
2001-07-12 |
2005-09-30 |
Jefferson Foote |
Anticuepros super humanizados.
|
|
US7091186B2
(en)
|
2001-09-24 |
2006-08-15 |
Seattle Genetics, Inc. |
p-Amidobenzylethers in drug delivery agents
|
|
WO2003026577A2
(en)
|
2001-09-24 |
2003-04-03 |
Seattle Genetics, Inc. |
P-amidobenzylethers in drug delivery agents
|
|
CA2467242A1
(en)
|
2001-11-20 |
2003-05-30 |
Seattle Genetics, Inc. |
Treatment of immunological disorders using anti-cd30 antibodies
|
|
ES2291620T3
(es)
|
2002-03-13 |
2008-03-01 |
Beijing Jiankai Technology Co., Ltd. |
Derivado de polimeros hidrfilicos con rama tipo y y metodo de preparacion de compuesto metodo que comprende el compuesto anterior.
|
|
US7456260B2
(en)
|
2002-06-17 |
2008-11-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Humanized antibody
|
|
US20060002935A1
(en)
|
2002-06-28 |
2006-01-05 |
Domantis Limited |
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
|
|
US9028822B2
(en)
|
2002-06-28 |
2015-05-12 |
Domantis Limited |
Antagonists against TNFR1 and methods of use therefor
|
|
AU2003294210A1
(en)
|
2002-07-31 |
2004-05-04 |
Seattle Genetics, Inc |
Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
|
GB0230203D0
(en)
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
|
CN1845938B
(zh)
|
2003-06-30 |
2010-05-26 |
杜门蒂斯有限公司 |
多肽
|
|
KR20120064120A
(ko)
|
2004-06-01 |
2012-06-18 |
제넨테크, 인크. |
항체 약물 접합체 및 방법
|
|
GB0521621D0
(en)
|
2005-10-24 |
2005-11-30 |
Domantis Ltd |
Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
|
|
EP1875247B1
(en)
|
2005-04-11 |
2011-02-02 |
Cambridge Enterprise Limited |
Selective modulation of tumour necrosis factor receptors in therapy
|
|
BRPI0713272A2
(pt)
|
2006-06-12 |
2017-05-02 |
Receptor Biologix Inc |
produtos terapêuticos específicos ao receptor na superfície de pan-células
|
|
PT2094728E
(pt)
|
2006-10-26 |
2013-05-27 |
Janssen Biotech Inc |
Métodos de adaptação de anticorpos monoclonais ao ser humano
|
|
GB0724331D0
(en)
|
2007-12-13 |
2008-01-23 |
Domantis Ltd |
Compositions for pulmonary delivery
|
|
CA2688433A1
(en)
*
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Methods for selecting protease resistant polypeptides
|
|
CN102321155A
(zh)
*
|
2008-12-19 |
2012-01-18 |
华中科技大学 |
Tnf结合肽和tnfr1封闭肽及其在治疗溃疡性结肠炎中的应用
|
|
CN102405236A
(zh)
|
2009-02-19 |
2012-04-04 |
葛兰素集团有限公司 |
改进的抗-tnfr1多肽，抗体可变结构域和拮抗剂
|
|
WO2011008814A2
(en)
|
2009-07-14 |
2011-01-20 |
Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation |
Multiplexed measurement of exogenous and endogenous dna
|
|
EP2453920A2
(en)
|
2009-07-16 |
2012-05-23 |
Glaxo Group Limited |
Antagonists, uses & methods for partially inhibiting tnfr1
|
|
BR112012010114A2
(pt)
|
2009-10-27 |
2017-08-08 |
Glaxo Group Ltd |
domínio variável único de imunoglobulina, ligante multiespecífico, antagonista, uso do antagonista, método para tratamento e/ou profilaxia de uma condição inflamatória em um paciente, ácido nucleico, vetor, e, célula hospedeira.
|
|
SE535380C2
(sv)
|
2011-01-31 |
2012-07-17 |
Fairchild Semiconductor |
Bipolär transistor i kiselkarbid med övervuxen emitter
|
|
WO2012172070A1
(en)
|
2011-06-17 |
2012-12-20 |
Glaxo Group Limited |
Tumour necrosis factor receptor 1 antagonists
|
|
SG2014010482A
(en)
*
|
2011-08-17 |
2014-04-28 |
Glaxo Group Ltd |
Modified proteins and peptides
|
|
WO2014040076A1
(en)
|
2012-09-10 |
2014-03-13 |
Xencor |
Methods of treating neurological diseases
|
|
PL2953634T3
(pl)
|
2013-02-07 |
2021-11-22 |
The General Hospital Corporation |
Sposoby namnażania lub zubożania limfocytów t-regulatorowych
|
|
WO2015104322A1
(en)
|
2014-01-09 |
2015-07-16 |
Glaxosmithkline Intellectual Property Development Limited |
Treatment of inflammatory diseases with non-competitive tnfr1 antagonists
|
|
EP3221362B1
(en)
*
|
2014-11-19 |
2019-07-24 |
F.Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies and methods of use
|
|
WO2017040312A1
(en)
|
2015-08-28 |
2017-03-09 |
The General Hospital Corporation |
Agonistic anti-tumor necrosis factor receptor 2 antibodies
|
|
KR20230079500A
(ko)
*
|
2015-09-18 |
2023-06-07 |
추가이 세이야쿠 가부시키가이샤 |
Il-8에 결합하는 항체 및 그의 사용
|
|
CA3023930C
(en)
|
2016-05-13 |
2025-09-23 |
The General Hospital Corporation |
TUMOR-ANTAGONISTIC ANTIBODIES OF THE NECROSIS FACTOR RECEPTOR SUPERFAMILY
|
|
US11142558B2
(en)
|
2017-04-06 |
2021-10-12 |
Universität Stuttgart |
Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivity
|
|
WO2019226750A1
(en)
|
2018-05-23 |
2019-11-28 |
Kantum Diagnostics, Inc. |
Methods of treating and preventing renal inflammation by inhibiting udp-hexose signaling
|
|
EP3927828A4
(en)
|
2019-02-21 |
2023-02-01 |
Enosi Life Sciences Corp. |
ANTIBODIES AND ENONOMERS
|